WallStSmart

Medtronic PLC (MDT)vsMyomo Inc (MYO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 86679% more annual revenue ($37.54B vs $43.26M). MDT leads profitability with a 13.9% profit margin vs -33.5%. MDT earns a higher WallStSmart Score of 68/100 (B-).

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99

MYO

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -3.60
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Intrinsic value data unavailable for MYO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

MYO1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
21.3%8/10

Revenue surging 21.3% year-over-year

Areas to Watch

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

MYO4 concerns · Avg: 3.5/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$55.45M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bull Case : MYO

The strongest argument for MYO centers on Revenue Growth. Revenue growth of 21.3% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Bear Case : MYO

The primary concerns for MYO are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.44 is elevated, increasing financial risk.

Key Dynamics to Monitor

MDT profiles as a value stock while MYO is a growth play — different risk/reward profiles.

MYO carries more volatility with a beta of 1.50 — expect wider price swings.

MYO is growing revenue faster at 21.3% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 29/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Myomo Inc

HEALTHCARE · MEDICAL DEVICES · USA

Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.

Want to dig deeper into these stocks?